|Bid||33.91 x 1200|
|Ask||36.05 x 900|
|Day's Range||33.87 - 36.03|
|52 Week Range||29.70 - 41.79|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.00|
Certara today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference.
2020 was the 7th consecutive year where 90% of new drug & biologic approvals by the FDA were received by Certara’s customers.
Certara will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on Thursday, March 4, 2021.